A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Abstract Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vacc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alba Marina Gimenez, Ahmed M. Salman, Rodolfo F. Marques, César López-Camacho, Kate Harrison, Young Chan Kim, Chris J. Janse, Irene S. Soares, Arturo Reyes-Sandoval
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/adecc0ad11fd480ebf4d67623bca4048
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adecc0ad11fd480ebf4d67623bca4048
record_format	dspace
spelling	oai:doaj.org-article:adecc0ad11fd480ebf4d67623bca40482021-12-02T17:41:18ZA universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles10.1038/s41598-021-96986-12045-2322https://doaj.org/article/adecc0ad11fd480ebf4d67623bca40482021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96986-1https://doaj.org/toc/2045-2322Abstract Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of PvCSP (VK210, VK247 and P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic P. berghei parasites expressing PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each PvCSP allelic variant. Immunized mice were challenged with two existing chimeric P. berghei parasite lines expressing PvCSP-VK210 and PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant, PvCSP-P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of P. vivax.Alba Marina GimenezAhmed M. SalmanRodolfo F. MarquesCésar López-CamachoKate HarrisonYoung Chan KimChris J. JanseIrene S. SoaresArturo Reyes-SandovalNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alba Marina Gimenez Ahmed M. Salman Rodolfo F. Marques César López-Camacho Kate Harrison Young Chan Kim Chris J. Janse Irene S. Soares Arturo Reyes-Sandoval A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
description	Abstract Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of PvCSP (VK210, VK247 and P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic P. berghei parasites expressing PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each PvCSP allelic variant. Immunized mice were challenged with two existing chimeric P. berghei parasite lines expressing PvCSP-VK210 and PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant, PvCSP-P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of P. vivax.
format	article
author	Alba Marina Gimenez Ahmed M. Salman Rodolfo F. Marques César López-Camacho Kate Harrison Young Chan Kim Chris J. Janse Irene S. Soares Arturo Reyes-Sandoval
author_facet	Alba Marina Gimenez Ahmed M. Salman Rodolfo F. Marques César López-Camacho Kate Harrison Young Chan Kim Chris J. Janse Irene S. Soares Arturo Reyes-Sandoval
author_sort	Alba Marina Gimenez
title	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
title_short	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
title_full	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
title_fullStr	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
title_full_unstemmed	A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
title_sort	universal vaccine candidate against plasmodium vivax malaria confers protective immunity against the three pvcsp alleles
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/adecc0ad11fd480ebf4d67623bca4048
work_keys_str_mv	AT albamarinagimenez auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT ahmedmsalman auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT rodolfofmarques auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT cesarlopezcamacho auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT kateharrison auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT youngchankim auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT chrisjjanse auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT irenessoares auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT arturoreyessandoval auniversalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT albamarinagimenez universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT ahmedmsalman universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT rodolfofmarques universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT cesarlopezcamacho universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT kateharrison universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT youngchankim universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT chrisjjanse universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT irenessoares universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles AT arturoreyessandoval universalvaccinecandidateagainstplasmodiumvivaxmalariaconfersprotectiveimmunityagainstthethreepvcspalleles
_version_	1718379724212797440

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Ejemplares similares